None listed
Conditions
Interventions
Intervention1: CHOLOROQUIN: 250 MG
Control Intervention1: MELOXICAM: 15MG
Sponsors
ARCF
Eligibility
Inclusion criteria
Inclusion criteria: Patients of either sex and  20 years of age Diagnosis of clinically suspected Chikungunya (classical/ probable ) Chronic RMS pains of at least 4 weeks duration post febrile onset Pains with a score of 4 on painVAS in past 24 hours Patients not receiving regular anti- inflammatory drug or analgesic drugs Willing to come for regular follow ? up visits Signed Informed Consent and patient information sheet
Exclusion criteria
Exclusion criteria: Confirmed diagnosis for febrile illness other then Chikungunya Patient with any other inflammatory form of arthritis Hypersensitivity to any of the study medication drugs Any condition that, in the opinion of the investigator, does not justify the patient?s inclusion for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PAIN VASTimepoint: 24 WEEKS- ONCE EVERY MONTH | — |
Secondary
| Measure | Time frame |
|---|---|
| JOINT COUNT FOR PAIN AND TENDERNESS JOINT COUNT FOR SWELLING PHYSICIAN GLOBAL ASSESSMENT PATIENT GLOBAL ASSESSMENT HEALTH ASSESSSMENT QUESTIONNAIRE PARACETAMOL CONSUMPTIONTimepoint: 24 WEEKS-ONCE EVERY MONTH | — |
Countries
India
Contacts
Public ContactARVIND CHOPRA
Outcome results
None listed